American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries; ranks 4th among biomedical firms by revenue and is currently the most valuable pharmaceutical manufacturer globally, having become the first healthcare firm to reach $1 trillion market cap (November 2025).
相关临床试验
182
35 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1876
进行中（未招募）
35
19.2%
已完成
6
3.3%
招募中
138
75.8%
暂停
3
1.6%
暂无批准数据
- A federal judge ruled that Eli Lilly can proceed with its lawsuit against Mochi Health Corp., a telehealth company selling compounded versions of tirzepatide drugs Zepbound and Mounjaro. - The court found that Lilly successfully demonstrated economic harm through diverted sales and reputational damage from consumer confusion between compounded and FDA-approved medications. - Studies cited in the case indicate higher adverse side effects among users of compounded GLP-1 inhibitors compared to FDA-approved formulations. - The ruling addresses concerns about corporate practice of medicine violations, where non-licensed business entities allegedly control medical decisions for profit rather than patient care.
- Trogenix's Synthetic Super-Enhancers achieved complete tumor elimination in 83% of treated glioblastoma cases with a single dose and no toxicity over 11 months. - The dual-payload gene therapy platform combines direct tumor killing with immune activation, creating durable protection against cancer recurrence. - The breakthrough pre-clinical data published in Nature supports the company's transition to clinical trials, with patient dosing expected in Q2 2026. - Fresh patient tissue validation demonstrated selective targeting of tumor cells while sparing healthy brain tissue, minimizing off-target toxicities.
- Johnson & Johnson will invest over $1 billion to build a next-generation cell therapy manufacturing facility in Lower Gwynedd, Montgomery County, Pennsylvania, scheduled to open in 2031. - The facility will create more than 500 bio-manufacturing jobs and will produce cutting-edge medicines for cancer, immune-mediated, and neurological diseases. - This investment is part of Johnson & Johnson's $55 billion commitment to U.S. manufacturing, research and development through early 2029, aimed at bringing advanced medicine production back to America. - Pennsylvania has secured $41 million in tax credits, grants, and workforce training funds for the project, marking the second major pharmaceutical investment in the state following Eli Lilly's $3.5 billion plant announcement.
- BioVie Inc. appointed Amy S. Chappell, MD, FAAN, and Kameel D. Farag to its Board of Directors to support the company's neurological and liver disease drug development programs. - Dr. Chappell brings 25 years of CNS drug development experience at Eli Lilly, including FDA approvals for Cymbalta in fibromyalgia and musculoskeletal pain indications. - The appointments coincide with BioVie's ongoing Phase 2 trials of bezisterim for early Parkinson's disease and long COVID, plus advancing Alzheimer's disease and liver cirrhosis programs. - Farag's financial expertise includes securing over $150 million in financing at Aspen Neuroscience and scaling operations at major pharmaceutical companies like Ionis and Amgen.
- A federal court ruled against Johnson & Johnson's proposal to shift from upfront drug discounts to a rebate model in the 340B Drug Pricing Program, which requires pharmaceutical manufacturers to sell outpatient drugs at reduced prices to healthcare providers serving low-income and rural populations. - Judge Rudolph Contreras determined that the US Health Resources and Services Administration acted within its authority and provided reasonable explanations for rejecting J&J's rebate model, which would have allowed covered entities to pay full list price and receive rebates later. - The decision represents a significant victory for hospitals and healthcare groups that rely on upfront 340B pricing to manage drug costs for vulnerable patient populations. - Johnson & Johnson plans to appeal the ruling, claiming it "contradicts the statute and allows for the continuing abuse and potential fraud that undermines the 340B Program's original intent."
- Phase 3 trial demonstrates pirtobrutinib's superior progression-free survival compared to idelalisib or bendamustine plus rituximab in previously treated chronic lymphocytic leukemia patients. - Real-world evidence reveals a significant 10-month extension between progression-free survival and time to next treatment, suggesting enhanced clinical benefits beyond trial results. - Study findings position pirtobrutinib (Jaypirca) as a promising therapeutic option for CLL patients who have received prior BTK inhibitor therapy.
- Novo Nordisk has launched Wegovy in China, with the 0.25 mg starter dose priced at 1,400 yuan ($193.31) per month. - This price is substantially lower than the $1,349 list price in the U.S., though Chinese patients will primarily pay out-of-pocket. - Wegovy is not currently covered by China's national health insurance, which covers 95% of the population, as weight-loss treatments are excluded. - China's obesity rates are rising, with an estimated 85 million adults affected, creating a significant market for weight-loss drugs.
- The European Medicines Agency's advisory panel has reversed its initial negative decision and now supports the use of Eisai's Leqembi for treating Alzheimer's disease. - Leqembi's use will be restricted to patients with one or no copy of the ApoE4 gene variant due to the increased risk of brain swelling and bleeding in those with two copies. - This decision marks a significant win for Eisai and its partners Biogen and BioArctic, potentially benefiting millions of Alzheimer's patients in Europe. - Leqembi has already been approved in the US, Japan, and China, and this EU backing could account for up to 30% of the drug's worldwide peak sales.
• Viking Therapeutics' obesity pill demonstrated an average of 6.8% body weight loss over 28 days in early-stage trials, showing promising potential in weight management. • AstraZeneca's weight-loss pill showed a 5.8% weight reduction in diabetic patients, indicating efficacy in a specific population with differential outcomes. • The obesity drug market is projected to reach $130 billion by the end of the decade, intensifying competition among pharmaceutical giants like Eli Lilly and Novo Nordisk. • Pharmaceutical companies are focusing on developing convenient oral medications with minimal side effects to capture a significant share of the expanding obesity treatment market.
• Viking Therapeutics' VK2735 oral therapy demonstrated a 3.3% placebo-adjusted weight loss after 28 days at a 40mg dose in Phase 1 trials. • The oral pill was well-tolerated, with no reports of vomiting or diarrhea, fueling optimism for higher doses and Phase 2 trials. • Analysts anticipate data supporting progression to Phase 2 trials for both oral and injectable versions, highlighting Viking's leading position in peptide incretins. • Scalability remains a key question, with potential implications for Viking as a takeover target amid the race for effective oral weight-loss treatments.
